Cyclo-oxygenase-2 in vascular smooth muscle (Review)

International Journal of Molecular Medicine

Volumn 3, Issue 1, 1999, Pages 41-48

  Bishop Bailey, David ^a   Hla, Timothy ^b   Mitchell, Jane A ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Adhesion; Atherosclerosis; Cyclo oxygenase 2; GM CSF; Proliferation; Vascular smooth muscle

Indexed keywords

CYCLOOXYGENASE 2; CYTOKINE; ISOENZYME; MEMBRANE PROTEIN; PROSTAGLANDIN SYNTHASE; PTGS2 PROTEIN, HUMAN;

ANIMAL; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE;

ANIMALS; CYCLOOXYGENASE 2; CYTOKINES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; MUSCLE, SMOOTH, VASCULAR; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; VASCULAR DISEASES;

EID: 0032608665     PISSN: 11073756     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Ross R: Atherosclerosis: a defense mechanism cone awry. Am J Pathol 143: 987-1002, 1995.
2. Moncada S, Gryglewski R, Bunting S and Vane JR: An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aacreeation. Nature 263:663-665, 1976.
3. Radomski MW, Palmer RMJ and Moncada S: The antiaggregating properties of vascular endothelium: interactions between prostacylin and nitric oxide. Br J Pharmacol 92: 639-646, 1987.
4. Williams TJ and Morley J: Prostaglandins as potentiators of increased vascular permeability in inflammation. Nature 246: 215-217, 1973.
5. Ferreira SH: Prostaglandin, aspirin-like druas and analgesia. Nature 240: 200-203, 1972.
6. Crofford LJ, Wilder RL, Ristimaki AP, Sano H, Remmers EF, Epps HR and Hla T: Cyclo-oxygcnasc-1, and -2 expression in rheumatiod synovial tissues. Effects of intcrleukin-1β, phorbol ester, and corticostcroids. J Clin Invest 93: 1095-1101, 1994.
7. Vane JR, Mitchell JA, Appleton I, Tomlinson A, Bishop-Bailey D, Croxtall J and Willoughby DA: Inducible isoforms of cyclooxygenase and nitric oxide synthasc in inflammation. Proc Natl Acad Sci USA 91: 2046-2050, 1994.
8. 2 enzymes: regulation and inhibition. TIPS 14: 92-98, 1993.
9. Hamberg M, Svensson J and Samuelsson B: A new concept concerning the mode of action of release of prostaelandins. Proc Natl Acad Sci USA 71: 3824-3828, 1974.
10. Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 231: 232-235, 1971.
11. Van der Ouderaa FJ, Buytenhek M, Nugteren DH and van Dorp DA: Acetylation of prostaglandin endoperoxide synthetase with acetylsalicylic acid. Eur J Biochem 109: 1-8, 1980.
12. 2α. J Biol Chem 270: 9800-9808, 1995.
13. Jourdan KB, Mitchell JA and Evans TW: Release of isoprostanes by human pulmonary artery in organ culture: a cyclo-oxygenase and nitric oxide dependent pathway. Biochem Biophys Res Commun 233: 668-672, 1997.
14. Miyamoto T, Ogmo N, Yamamoto S and Hayaishi O: Purification of prostaglandin endoperoxide synthetasc from bovine vesicular eland microsomcs. J Biol Chcm 263: 3550-3553, 1976.
15. DeWitt DL and Smith WL: Primary structure of prostaglandin G/H synthasc from sheep vesicular gland determined from the complementary DNA sequence. Proc Natl Acad Sci USA 85: 1412-1416, 1988.
16. Bailey JM, Muza B, Hla T and Salata K: Restoration of prostacyclin synthasc in vascular smooth muscle after aspirin treatment: regulation by epidermal growth factor. J Lipid Res 26: 54-61, 1985.
17. Xie W, Chipman JG, Robertson DL, Erikson RL and Simmons DL: Expression of a mitogen-responsive gene encoding prostaglandin synthase is rcsulated by mRNA splicing. Proc Natl Acad Sci USA 88: 2692-2696, 1991.
18. Kujubu DA, Fletcher BS, Varnum BC, Lim RW and Herschman HR: TIS 10, a phorbol ester tumour promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthasc/cyclooxycenase homologue. J Biol Chem 266: 12866-12872, 1991.
19. Hla T and Niclson K: Human cycIooxygcnasc-2 cDNA. Proc Natl Acad Sci USA 89: 7384-7388, 1992.
20. Mitchcll JA, Larkin SW and Williams TJ: Cyclo-oxygcnasc-2: regulation and relevance in inflammation. Biochem Pharmacol 50: 1535-1542, 1995.
21. O'Banion MK, Winn VD and Young DA: cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygcnase. Proc Natl Acad Sci USA 89: 4888-4892, 1992.
22. Smith WL, Gravavito M and DeWitt DL: Prostaglandin endopcroxidc H synthascs (cyclooxygenases)-1 and -2. J Biol Chem 271: 33157-33160, 1996.
23. Mcade EA, Smith WL and DeWitt DL: Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other nonstcriodal antiinflammatory drues. J Biol Chem 268: 6610-6614, 1983.
24. Mitchell JA, Akarascrcenont A, Thiemermann C, Flower RJ and Vane JR: Selectivity of nonstcriodal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 90: 11693-11697, 1993.
25. Futaki N, Takahashi S, Yokohama M, Arai I, Higuchi S and Otomo S: NS-398 a new anti-inflammatory agent, selectively inhibits prostaglandin synthasc/cyclooxygenasc (COX-2) activity in vitro. Prostaglandins 47: 55-59, 1994.
26. Chan CC, Boyce S, Bridcau C, Ford-Hutchinson AW, Gordon R, Guay D, Hill RG, Li CS, Mancini J, Penneton M, Prasit P, Rasori R, Riendeau D, Roy P, Tagaui P, Vickers P, Wong W and Rodgcr IW: Pharmacology of a selective cyclo-oxygenase-2 inhibitor, L-745,337: a novel nonsteriodal anti-inflammatory agent with an ulcerocenic sparing effect in rat and nonhuman primate stomach. J Pharmacol Exp Ther 274: 1531-1537, 1995.
27. Pritchard KA, O'Banion MK, Miano JM, Vlasic N, Bhatia UG, Young DA and Stemerman MB: Induction of cyclo-oxygenase-2 in rat vascular smooth muscle cells in vitro and in vivo. J Biol Chem 269: 8504-8509, 1994.
28. Rimarachin JA, Jacobson JA, Szabo P, Maclouf J, Creminon C and Weksler BB: Regulation of cyclooxygenase-2 expression in aortic smooth muscle cells. Artcrioscler Tliromb 14: 1021-1031, 1994.
29. Shimokawa H, Ito A, Fukumoto Y, Kadokami T, Nakaikc R, Sakata M, Takayanagi T, Egashira K and Takcshita A: Chronic treatment with intcrlcukin-l induces coronary intimai lesions and vasospastic responses in pigs in vivo. J Clin Invest 97: 769-776, 1996.
30. Libby P, Warner SJC and Friedman GB: Intcrleukin-1: a mitogen for human vascular smooth muscle cells that induces the release of crowth-inhibitory prostanoids. J Clin Invest 81: 487-498, 1988.
31. Smith WL: Prostaglandin biosynthesis and its conipartmentation in vascular smooth muscle and cndothclial cells. Annu Rev Physiol 48: 251-262, 1986.
32. Eldor A, Falcone DJ, Hajjar DP, Minick CR and Weksler BB: Recovery of prostacyclin production by deendothclialized rabbit aorta: critical role of the ncointimal smooth muscle cells. J Clin Invest 67: 735-741, 1981.
33. Hcnrion D, Dcchaux E, Dowell FJ, Maclouf J, Samuel JL, Levy BI and Michel JB: Alteration of flow-induced dilatation in mesenteric resistance arteries of L-NAME treated rats and its partial association with induction of cyclo-oxygcnasc-2. Br J Pharmacol 121:83-90, 1997.
34. Bishop-Bailey D, Pepper JR, Haddad E-L, Newton R, Larkin SW and Mitchcll JA: Induction of cyclo-oxygenase-2 in human saphcnous vein and internal mammary artery. Arterioscler Thromb Vase Biol 17: 1644-1648, 1997.
35. Bishop-Bailey D, Larkin SW, Pepper JR and MitchcII JA: Differential induction of cyclo-oxygcnase-2 human venous and arterial vascular smooth muscle cells: role of endogenous prostanoids. Artcrioscler Thromb Vase Biol 18: 1655-1661. 1998.
36. 2α to regulate initiation of DNA replication and cell division in Swiss 3T3 cells. Proc Natl Acad Sci USA 79: 4992-4996, 1982.
37. Hara S, Morishita R, Tone Y, Yokoyama C, Inoue H, Kancda Y and Tanabe T: Ovcrexpression of prostacyclin synthase inhibits growth of vascular smooth muscle cells. Biochem Biophys Res Commun 216: 862-867, 1995.
38. Sachinidis A, Flesch M, Schror K, Bohm M, Dusing R and Vetter H: Thromboxanc Ai and vascular smooth muscle proliferation. Hypertension 26: 771-780, 1995.
39. Bornfeldt KE, Campbell JS, Koyama H, Argast GM, Leslie CC, Raines EW, Krebs EG and Ross R: The mitogen-activated protein kinasc pathway can mediate crowth inhibition and proliferation in smooth muscle cells. J Clin Invest 100: 875-885, 1997.
40. Bishop-Bailey D, Pepper JR, Larkin S, Evans T and Mitchell JA: Interleukin-1β induces anti-proliferative prostanoids via cyclooxygenase-2 in human saphenous vein and internal mammary artery smooth muscle cells. Br J Pharmacol 122: P20, 1997.
41. Springer T: Traffic signals for lymphocyte recruitment and leukocyte emigration: the multistcp paradigm. Cell 76: 301-314, 1994.
42. Faruqi RM and DiCorlcto PE: Mechanisms of monocyte recruitment and accumulation. Br Heart J 69: S19-29, 1993.
43. Yasukawa H, Imaizumi T, Matsuoka H, Nakashima A and Morimatsu M: Inhibition of intimai hyperplasia after ballon injury by antibodies to intercellular adhesion molecule-1 and lymphocyte function associated antigcn-1. Circulation 95: 1515-1522, 1997.
44. Mariin SD and Springer T: Purified intercellular adhesion molecule-1 (ICAM-1) is a lipid for lymphocyte function associated antigen 1 (LFA-1). Cell 51: 813-819, 1987.
45. Osborn L, Hession C, Tizard R, Vassallo C, Luhowskyj S, Chi-Rosso G and Lobb R: Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell 59: 1203-1211, 1989.
46. Ikeda U, Ikeda M, Seino Y, Takahashi M, Kasahara T, Kano S and Shimada K: Expression of intercellular adhesion molecule-1 on rat vascular smooth muscle cells by pro-inflammatory cytokincs. Atherosclerosis 104: 61-68, 1993.
47. Couffinhal T, Duplaa C, Moreau C, Lamazicre JM and Bonnet J: Regulation of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 in human vascular smooth muscle cells. Circ Res 74: 225-234, 1994.
48. Libby P and Li H: Vascular cell adhesion molecule-1 and smooth muscle cell activation during atherogenesis. J Clin Invest 92: 538-539, 1993.
49. Poston RN, Haskard DO, Coucher JR, Gall NP and Johnson-Tidey RR: Expression of intercellular adhesion molecule-1 in atherosclerotic plaques. Am J Pathol 140: 665-673, 1992.
50. Printseva OYU, Peclo MM and Gown AM: Various cell types in human atherosclerotic lesions express ICAM-I. Further immunochemical studies employing monoclonal antibody 10F3. Am J Pathol 140: 889-896, 1992.
51. O'Brien KD, Allen MD, McDonald TO, Chait A, Harlan JM, Fishbein D, McCarty J, Ferguson M, Hudkins K and Benjamin CD: Vascular cell adhesion molecule-1 is expressed in human coronary atherosclerotic plaques. Implications for the mode of progression of advanced coronary atherosclerosis. J Clin Invest 92: 945-951, 1993.
52. Bishop-Bailey D, Burke-Gaffney A, Hellewell P, Pepper JR and Mitchell JA: Interleukin (IL)-1β induced cyclo-oxygenase-2 activity inhibits expression of ICAM-1 and VCAM-1 on human vascular smooth muscle cells. Biochem Biophys Res Commun 249: 44-47, 1998.
53. Mitchell JA, Bishop-Bailey D, Evans TW, Giembycz MA, Belvisi MG, Chivers S, Williams TJ and Pepper JR: Role of cyclo-oxygenase-2 in the suppression of GM-CSF release by cultures of human arterial and venous smooth muscle cells. Br J Pharmacol (In press).
54. Hajjar DP and Pomerantz KB: Signal transduction in atherosclerosis: intergration of cytokines and the cicosanoid network. FASEBJ 6: 2933-2941, 1992.
55. Topper JN, Cai J, Falb D and Gimbrone MA: Identification of vascular endothclial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci USA 93: 10417-10422, 1996.
56. Zembowicz A, Jones SL and Wu KK: Induction of cyclo-oxygcnase-2 in human umbilical vein endothelial cells by lysophosphatidylcholine. J Clin Invest 96: 1688-1692, 1995.
57. Zoldhelyi P, McNatt J, Xu XM, Loose-Mitchell D, Mcidell RS, Clubb FJ, Buja LM, Willerson JT and Wu KK: Prevention of thrombosis by adenovirus-mediated transfer of cyclooxycenase gene. Circulation 93: 10-17, 1996.
58. Pomerantz KB, Summers B and Hajjar DP: Eicosanoid metabolism in cholesterol-enriched arterial smooth muscle cells. Evidence for posttranscriptional processing of cyclooxygenase I and reduced cyclooxygenase II gene expression. Biochemistry 32: 13624-13635, 1993.
59. Bishop-Bailey D, Larkin SW, Warner TD, Gong C and Mitchell JA: Characterisation of the induction of inducible nitric oxide synthase and cyclo-oxygenase-2 in the rat aorta in organ culture. Br J Pharmacol 121: 125-133, 1997.
60. Salmon JA, Smith DR, Flower RJ, Moncada S and Vane JR: Further studies on the enzymatic conversion of prostaglandin endoperoxide into prostacyclin by porcine aorta microsomes Biochim Biophys Acta 523: 250-262, 1978.
61. Eguchi Y, Eguchi N, Oda H, Sciki K, Kijima Y, Matsu-Ura Y, Urade Y and Hayaishi O: Expression' of lipocalin-type prostaglandin D synthase (β-trace) in human heart and its accumulation in the coronary circulation of angina patients. Proc Natl Acad Sci USA 94: 14689-14694, 1997.
62. Willis AL, Smith DL and Vigo C: Suppression of principal atherosclerotic mechanisms by prostacyclins and other eicosanoids. Prog Lipid Res 25: 645-666, 1986.
63. Simon TC, Makheja AN and Bailey JM: The induced lipoxygenase in atherosclerotic aorta converts linolcic acid to the platelet chemorepellant factor 13-HODE. Thromb Res 55: 171-178, 1989.
64. 2 is a ligand for the adipocyte determination factor PPARy. Cell 83: 803-812, 1995.
65. 2 metabolite binds peroxisone proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 83: 813-819, 1995.
66. Tontonoz P, Nagy L, Alvarez JGA, Thomazy VA and Evans RM: PPARγ promotes monocyte/macrophage differentiation and uptake of oxidised LDL. Cell 93: 241-252, 1998.
67. Chinetti G, Griglio S, Antonucci M, Terra IP, Delerive P, Majd Z, Fruchart J-C, Chapman J, Najib J and Staels B: Activation of proliferator-activater receptors α and γ induces apoptosis of human monocyte-derived macrophages. J Biol Chem 273: 25573-25580, 1998.
68. Bishop-Bailey D, Larkin SW, Pepper JR, Yacoub MH, Williams TJ and Mitchell JA: Comparison of the ability of human, rat and rabbit vessels to produce nitric oxide and prostanoids in response to LPS. Br J Pharmacol 117: 78P, 1996.
69. Bishop-Bailey D, Larkin SW, Williams TJ and Mitchell JA: Roles of nitric oxide and COX-metabolites in proliferation of rat aortic segments in organ culture. Br J Pharmacol 119: 77P, 1996.
70. Woods M, Bishop-Bailey D, Pepper JR, Larkin S, Mitchell JA and Warner TD: Cytokine and lipopolysaccharide stimulation of endothelin-1 release from internal mammary and saphenous vein smooth muscle cells. J Cardiovasc Pharmacol 31 (Suppl. 1): S348-350, 1998.